CSL's Bird Flu Vaccine Receives Approval

June 2008 | Product Launch

Boosting Australia's reputation for high quality biomedical R&D, the Therapeutic Goods Administration (TGA) has approved local firm CSL's avian influenza vaccine, Panvax. Launch will only be sanctioned by the government in the event of a pandemic, so no sales are expected until 2009 at the earliest, or perhaps none at all. Nevertheless, BMI believes the news will attract more drugmakers to partner with CSL, which was instrumental in the development of Merck & Co's breakthrough cervical cancer vaccine, Gardasil.

If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.